English
Русский
O'zbek
ЛЕЧЕНИЕ ГИПЕРКОАГУЛЯЦИОННОГО СИНДРОМА АНТИКОАГУЛЯНТНЫМ ПРЕПАРАТОМ У БОЛЬНЫХ С COVID-19
Общая информация о статье
Илмий мақоладаCOVID-19 билан касалхонага ётқизилган беморларда веноз тромбоэмболизмнинг олдини олиш учун Rivaroksabanдан фойдаланиш хавфсизлиги ва самарадорлиги тақдим этилди.
1. Cuker A., Tseng EK., NieuwlaatR. et al. American Society of Hematology 2021 guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19.Blood Adv (2021) 5 (3): 872–888.
2. Di Micco P, Russo V, Carannante N, Imparato M, Rodolfi S, Cardillo G, et al. Clot ting factors in COVID-19: epidemiological association andprognostic values in dif ferent clinical presentations in an Italian Cohort.JClin Med. (2020) 9:1371.
3. Fontana P, Casini A, Robert-Ebadi H, Glauser F, Righini M, Blondon M. Venous thromboembolism in COVID-19: systematic review of reported risks and current guidelines. Swiss Med Wkly. (2020) 150:w20301.
4. Jose RJ, Manuel A. COVID-19 cytokine storm: the interplay between inflammation and coagulation. Lancet Respir Med. (2020) 8:e46–7.
5. Konstantinides SV, Meyer G, Becattini C, Bueno H, Geersing GJ, Harjola VP, et al. ESC Scientific Document Group developed in collaboration with the European Res piratory Society (ERS). Eur Heart J. (2020) 41:543–603.
6. Levi M., M. Scully, How I treat disseminated intravascular coagulation. Blood. (2018) 131:845–54.
7. McCloskey B, Heymann DL. SARS to novel coronavirus: old lessons and new les sons. EpidemiolInfect. (2020) 148:e22.
8. Moores LK, Tritschler T, Brosnahan S, Carrier M, Collen JF, Doerschug K, et al. Prevention, diagnosis, and treatment of VTE in patients with coronavirus disease 2019: CHEST guideline and expert panel report. Chest. (2020) 158:1143–63.
9. Russo V, Bottino R, Carbone A, Rago A, Papa AA, Golino P, et al.COVID-19 and heart: from clinical features to pharmacological implications.JClin Med. (2020) 9:E1944.
10. Russo V, Rago A, Carbone A, Bottino R, Ammendola E, Della Cioppa N, et al. Atrial fibrillation in COVID-19: from epidemiological association to pharmacological im plications. J CardiovascPharmacol. (2020) 76:138–45.
11. Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopa thy. J ThrombHaemost. (2020) 18:1094– 9.
12. Mega JL, Braunwald E, Wiviott SD, et al; ATLAS ACS 2–TIMI 51 Investigators. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med 2012;366(01):9–19.
13. Eikelboom JW, Connolly SJ, Bosch J, et al; COMPASS Investigators. Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med 2017;377(14):1319–1330.
14. Cohen AT, Spiro TE, Büller HR, et al; MAGELLAN Investigators. Rivaroxaban for thromboprophylaxis in acutely ill medical patients. N Engl J Med 2013;368(06):513 523.
15. Spyropoulos AC, Ageno W, Albers GW, et al; MARINER Investigators. Rivaroxa banfor thromboprophylaxis after hospitalization for medical illness. N Engl J Med 2018;379(12):1118–1127.
16. Cohen AT, Harrington RA, Goldhaber SZ, et al; APEX Investigators. Extended thromboprophylaxis with betrixaban in acutely ill medical patients. NEnglJMed 2016;375(06):534–544.
17. Временные методические рекомендации по профилактике, диагностике, лече нию и реабилитации прикоронавирусной инфекции(COVID-19), Версия 8, 2020. (03.09.2020).
18. Громов А.А.,КручининаМ.В.,Рабко А.В.Коронавирусная болезнь COVID-19: неиспользованные возможности терапии.РМЖ. 2020, №9. С.2-6.
, С. ., & , . . (2026). ЛЕЧЕНИЕ ГИПЕРКОАГУЛЯЦИОННОГО СИНДРОМА АНТИКОАГУЛЯНТНЫМ ПРЕПАРАТОМ У БОЛЬНЫХ С COVID-19. ALFRAGANUS, 6(4), 74–81. https://doi.org/
, Сабитходжаева С.У., and Шодиева Г.Р. ,. “ЛЕЧЕНИЕ ГИПЕРКОАГУЛЯЦИОННОГО СИНДРОМА АНТИКОАГУЛЯНТНЫМ ПРЕПАРАТОМ У БОЛЬНЫХ С COVID-19.” Academic Research in Educational Sciences, vol. 4, no. 6, 2026, pp. 74–81, https://doi.org/.
, . and , . 2026. ЛЕЧЕНИЕ ГИПЕРКОАГУЛЯЦИОННОГО СИНДРОМА АНТИКОАГУЛЯНТНЫМ ПРЕПАРАТОМ У БОЛЬНЫХ С COVID-19. Academic Research in Educational Sciences. 4(6), pp.74–81.